Belviq And Qsymia Reviews

Very recently the FDA approved not one but two new weight loss drugs. Given the past serious problems with weight loss drugs, it's the controversy surrounding their prescription in the growing obesity epidemic in the United States, our article reports on the efficacy of these drugs the potential risk and the hopeful benefit.

Weight Loss Drugs History

belviq and qsymia review

In July 2012 the FDA approved two new weight-loss drug - Belviq and Qsymia for long-term use with an aim to help reduce the obesity epidemic. The approval with a paramount decision, which will have many short and long-term effects. This is the first time in nearly 13 years that the FDA has approved two drugs for long-term treatment of obesity.

Before this Orlistat was the only approved prescription as a long-term weight loss drug. Orlistat is also sold in a lower dose over the counter.

The first weight loss drugs approved by the FDA was methamphetamine in 1947, which was used as an appetite suppressant. Then, in 1973 amid concerns about epidemic rates of them 17 youth the FDA limited all weight loss drugs to short-term use only.

For example, Fen-Phen was removed from the market in 1997 due to concerns regarding damage to a heart valve.

Lastly, in 2010 Meridia was also removed due to an increased risk of heart attack and stroke in patients.


Belviq works by activating the serotonin 2C receptor in a brain. Due to this a person will likely eat less between meals and feel more satisfied with less food. Belviq is similar to appetite suppression drugs Fen-Phen, which was pulled from the market in 1997 due to a link between the drugs and fatal heart valve problems.

At a lower dose, Belviq is considered to be safe. However, there has only been a few clinical trials.

Dr. Donna Ryan, a researcher and obesity specialist at the Pennington Biomedical Research Center, conducted studies of this two medications for the drug company. She reported that Belviq was developed specifically to avoid the receptor on the heart valve, which had been associated with heart damage. There is no evidence in her research that heart valve problems will develop.


Qsymia is a combination of two FDA-approved drugs – phentermine, an appetite suppressant, and topiramate, which is used to treat epilepsy and migraines. Even at the lowest dose, Qsymia shows more promising results than Belviq, perhaps, because it's a double ingredient drug combining the appetite suppressant of phentermine with an anticonvulsant drugs topiramate, which has been previously indicated to in weight loss due to its effect of feeling fuller after eating.

Side Effects Of Belviq And Qsymia

Both drugs have a long list of potential side effects. Common side effects from either drug may include dry mouth, constipation and tingling of the fingers and toes.

In addition to the side effects listed Belviq may also cause problems with attention and memory and can also interact with other medications used to treat migraine headaches and depression.

In patients with diabetes, additional side effects of Belviq include low blood sugar, cough and back pain. Concerning the side effects associated with leukemia also includes increased heart rate and blood pressure, depression, confusion, psychosis, and insomnia.

Pregnant women are discouraged from using Qsymia due to possible birth defects.

Belviq Clinical Trials

The FDA evaluated three randomized placebo-controlled trials of nearly 8,000 obese and overweight adults with and without type 2 diabetes. Participants were followed for one or two years and all participants received exercise counseling and followed a reduced-calorie diet.

When compared to the placebo group, participants who were treated with Belviq for up to one year experienced a weight loss between 3% and 3.7%. There was no statistically significant difference in the development of heart valve abnormalities between Belviq and placebo groups.

Qsymia Clinical Trials

The safety and efficacy of Qsymia were evaluated in two multicenter phase three trials - the equip study and the conquer study. These two studies included more than 3,700 patients who were treated for up to one year.

In order to participate patients had to be severely obese to the BMI of at least 30 or who were overweight with a BMI of at least 27, who was also suffering from at least one weight-related comorbidities such as hypertension or type 2 diabetes.

The average weight loss was 10.9% on a combination of Qsymia of 15 milligrams and 92 milligrams versus 1.6% weight loss to the placebo group. On average, weight loss in the second study was 9.8% on Qsymia 15 and 8% on 7.5 and 46 milligrams and 1.2% weight loss for the placebo group.

The average weight loss of patients taking Qsymia ranged from 6.7% at the lowest dose to 8.9% at the recommended dose over those taking a placebo.

How To Take Qsymia?

Qsymia is taken once a day with patients starting at the lowest dose of 3.75 milligrams of phentermine and 23 milligrams of topiramate extended-release. This is then increased to the recommended dose of 7.5 and 46 milligrams.

In some circumstances, patients may have their dose increased to the highest dose, which would be 15 milligrams of phentermine and 92 milligrams of topiramate extended-release.

Around 62% of patients on the lowest dose and 70% on the recommended dose lost at least 5% of their weight compared with 20% percent treated with the placebo.

After 12 weeks if a patient has not lost three percent of his or her weight on the recommended dose of Qsymia, the FDA recommends that treatment is discontinued or increased to the highest dose. If after an additional 12 weeks on the highest dose a patient does not lose at least five percent of their weight, Qsymia should be discontinued gradually.

The Obesity Epidemic

No longer seen only as a vanity related problems, obesity has been making national headlines and increasing numbers. With record numbers of cases of weight-related disease Americans around the study health decline.

Two studies published this year shone a light on just how grim outlook is. CDC study published in May suggestions that while the number of obese will continue to rise, the pace of that increase has slowed overall and has flatlined for women. Despite that seemingly good news, the numbers also reflect that the largest increase is among the severely obese. A projected increase of 130%.

The trust for America's health study published in September estimates that 39 states will have an obese population of over 50%. In 13 of those states that number chops 66%.

While there is no one accurate measure of health care costs specifically related to obesity, the trust for America's health study estimates that the annual cost of treating diseases related to obesity will increase 48 billion dollars annually. While the CDP anticipates that the annual total to reach 545.9 billion dollars by the year 2030.

While there is some controversy surrounding the accuracy at the body mass index scale, it is currently the go-to measure one's body fat based on high and weight. According to the scale, which compares only your height to weight ratio, underway is reflected by a score of less than 18.5. Normal weight shows 18.5 to 25, overweight 25 to 29.9. And the score of 30 or greater reflects obesity.

While these numbers may be skewed for those who are heavy due to high muscle mass, it is believed that the overall average reflects accuracy.

Belviq And Qsymia are approved for use in adults with a BMI of 30 or higher. They are also approved for adults with a BMI that least 27 who are currently experiencing at least one weight-related condition such as hypertension, type 2 diabetes or high cholesterol.

More on Belviq And Qsymia

Both Belviq And Qsymia help people to eat less food by decreasing hunger between meals and making you feel more satisfied with less food. However, neither drug helps boost metabolism. While taking either medications patients are also encouraged to reduce their food intake and engage in regular exercises.

With the average weight loss of 4%-8% over the one to two-year trials the drugs seem to have a promising effect. However, as both are intended to be lifelong prescriptions rather than short-term aids, the long-term effects on overall weight loss remain to be seen. In addition, even past serious side effects of weight loss drugs, most notably heart condition. Further studies are required of both drugs to monitor patients overall health.

Where To Buy Qsymia And Belviq Online?

You need to have a prescription to buy Qsymia and Belviq. However, you can purchase Qsymia and Belviq online without a prescription from various pharmacies over the Internet.


With regards to Qsymia, the ingredient phentermine may be habit-forming and is considered a classified drug and therefore should be used only by the person for whom it was prescribed.

In addition, patients should not stop taking Qsymia suddenly or seizures may result. It is necessary to gradually reduce the doses before stopping the medication completely in order to help avoid these features.

Belviq has shown a potential increase in the risk of priapism in men who are predisposed. Those condition results in long-lasting erections and can ultimately lead to erectile dysfunction.

As both drugs are intended for lifelong use, it is important for doctors to stress the need for proper diet and increased exercise levels. Without long-term weight loss numbers, it is unknown if there will be a need to decrease dosage over time. The thinking currently is that obesity should be considered a lifelong problem and should be treated as such.

Belviq And Qsymia Questions

While early studies of Belviq And Qsymia show promising results, we still have some questions. With the intention of these drugs as the life on prescriptions, why are we overlooking the need for education and behavior modification?

Too often weight loss drugs are seen as fast fixes and crash diets. We need to make sure that the focus here is on educating a patient for the long term not just supplying them with the drugs to help them change their weight without changing your behavior.

Since patients with obesity-related health problems like hypertension and diabetes are targeted, should we be more concerned with the reported side effects of increased heart rate and blood pressure, lower insulin levels, increased risk for glaucoma?

In addition, how will this drug be monitored? Patients are required to meet specific weight loss numbers in order to continue taking either drug. But how will continue with prescriptions from different doctors be monitored? Will patients pay you back from the doctor to doctor in order to receive new prescriptions that their previous doctors might have canceled?

By all accounts, our nation's obesity epidemic has the potential to crush both our health and our wealth.